Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 14INDUSTRY 3OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Sarcoma 2Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 278Lung Neoplasms 257Small Cell Lung Carcinoma 82Breast Neoplasms 59Mesothelioma, Malignant 49Adenocarcinoma of Lung 43Pancreatic Neoplasms 37Colonic Neoplasms 37Neoplasms 32Prostatic Neoplasms 30Ovarian Neoplasms 28Esophageal Neoplasms 26Neoplasm Metastasis 24Mesothelioma 24Melanoma 24Adenocarcinoma, Bronchiolo-Alveolar 24Stomach Neoplasms 22Colorectal Neoplasms 22Carcinoma, Renal Cell 22Rectal Neoplasms 20Urinary Bladder Neoplasms 18Uterine Cervical Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Carcinoma, Hepatocellular 17Brain Neoplasms 17Lymphoma, Non-Hodgkin 16Carcinoma, Ovarian Epithelial 16Thymoma 15Salivary Gland Neoplasms 15Lymphoma 15

Interventions

Monatide (IMS 3015) 1Biological Assay 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasm, Residual × Thoracic × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡